Anti-leukemic properties of IL-12, IL-23 and IL-27: Differences and similarities in the control of pediatric B acute lymphoblastic leukemia

Claudia Cocco, Vito Pistoia, Irma Airoldi

Research output: Contribution to journalArticle

Abstract

B acute lymphoblastic leukemia (ALL) is the most common pediatric hematologic malignancy. Although patient cure has reached an excellent rate, a minority of cases relapse and need novel therapies.IL-12, IL-23 and IL-27 belong to the IL-12 superfamily and exert immunological and anti-tumor functions. The latter can be mediated by activation of immune responses or by the direct activity on cancer cells. Recently, the role of IL-12, IL-23 and IL-27 in the control of pediatric B-ALL has been unveiled. Here, we discuss in a translational perspective the role of IL-12 family cytokines in pediatric B-ALL, highlighting similarities and differences in their mechanisms of action.

Original languageEnglish
Pages (from-to)310-318
Number of pages9
JournalCritical Reviews in Oncology/Hematology
Volume83
Issue number3
DOIs
Publication statusPublished - Sep 2012

Keywords

  • B-ALL
  • Cytokine receptors
  • Cytokines

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Fingerprint Dive into the research topics of 'Anti-leukemic properties of IL-12, IL-23 and IL-27: Differences and similarities in the control of pediatric B acute lymphoblastic leukemia'. Together they form a unique fingerprint.

  • Cite this